

Outthink. Outperform.

## Hiccups from new hospitals continue

IHH's 2Q17 net profit increased to RM316.6m (29% yoy), but core net profit declined 50% yoy if we exclude gains from the partial divestment of non-core assets. While IHH's core hospital operations in Malaysia and Singapore are seeing earnings growth, higher new hospital start-up costs, pre-operating costs, amortization and finance cost continue to drag IHH's profit. As these headwinds may persist, we maintain a HOLD rating with an unchanged TP of RM6.56.

### Solid revenue growth dampened by new hospital costs

IHH's 2Q17 revenue rose by 12% yoy to RM2.771bn, on the back of 10-30% revenue growth across major key markets. However, EBITDA declined 8% yoy due to higher pre-opening and start-up losses from new hospitals. Gleneagles Hong Kong (GHK) which opened in March 2017 saw EBITDA losses widened to RM67.8m in 2Q17 (1Q17: RM81.1m). On the other hand, Acibadem's EBITDA declined 9% yoy due to lower utilisation at Acibadem Kadikoy and Acibadem Kozyatagi, following the decanting of patients with complex conditions to Acibadem Altunizade. Higher operating costs and depreciation of Turkish Lira were also the culprits.

### Disposal gain saved bottom line

The higher 2Q17 headline net profit of RM 316.6m (+29%yoy) was only due to a gain on disposal of the remaining 4.78% stake in Apollo Hospital, which amounted to RM241m. Excluding EIs, core net profit declined by 50% yoy to RM86.2m, mainly due to higher depreciation (+22%yoy), amortisation (+11%yoy) and finance costs (+60%yoy), following the opening of 2 new hospitals in Hong Kong and Istanbul in March 2017. At the EBITDA level, 1H17 accounted for 42% of our and consensus full year forecast, which we deem as largely in line as we expect higher EBITDA in 2H17 as 2 new hospitals which opened in March, to continue to ramp up operations. However, core net profit of RM288m fell short, accounting for 30% of our 2017 forecast, below our and consensus' estimates.

### Maintain HOLD with unchanged DCF-derived TP of RM6.56

We lowered our core net profit by 6% to 10% for 2017-19E taking into account higher depreciation and finance cost. IHH's borrowings has increased by RM513m for working capital, capex, and potentially acquisition. While we like IHH for its aggressive expansion into regions where healthcare demand is underserved, we are concerned over prolonged losses arising from the new hospitals. Trading at a 2017 PE of 57x, we find the premium valuation unattractive at this level. Maintain Hold.

### Earnings & Valuation Summary

FYE 31 Dec	2015	2016	2017E	2018E	2019E
Revenue (RMm)	8,455.5	10,021.9	11,685.3	13,541.6	15,166.9
EBITDA (RMm)	2,164.4	2,267.2	2,655.5	3,252.5	3,787.0
Pretax profit (RMm)	1,217.5	877.6	1,828.8	1,767.3	2,225.4
Net profit (RMm)	933.9	612.4	1,420.7	1,229.6	1,560.7
EPS (sen)	11.4	7.4	17.3	14.9	19.0
PER (x)	52.7	80.7	34.8	40.2	31.6
Core net profit (RMm)	899.2	866.0	867.8	1,229.6	1,560.7
Core EPS (sen)	11.0	10.5	10.5	14.9	19.0
Core EPS growth (%)	14.3	(4.0)	0.2	41.7	26.9
Core PER (x)	54.8	57.0	56.9	40.2	31.6
Net DPS (sen)	3.0	2.0	4.6	3.9	5.0
Dividend Yield (%)	0.5	0.3	0.8	0.7	0.8
EV/EBITDA (x)	25.9	24.9	20.9	16.9	14.1
Chg in EPS (%)			(9.7)	(6.5)	(5.5)
Affin/Consensus (x)			0.9	1.0	1.0

Source: Company, Affin Hwang estimates

## Results Note

# IHH Healthcare

IHH MK

Sector: Healthcare &amp; Pharmaceuticals

RM6.00 @ 23 August 2017

HOLD (maintain)

Upside: 9 %

Price Target: RM6.56

Previous Target: RM6.56



## Price Performance

	1M	3M	12M
Absolute	-0.2%	2.4%	-10.2%
Rel to KLCI	-0.9%	2.1%	-14.7%

## Stock Data

Issued shares (m)	8,239.1
Mkt cap (RMm)/(US\$m)	49,343/11,549
Avg daily vol - 6mth (m)	6.0
52-wk range (RM)	5.54-6.71
Est free float	18.6%
BV per share (RM)	2.73
P/BV (x)	2.20
Net cash/ (debt) (RMm)	(3,431)
ROE (2018E)	6%
Derivatives	Nil
Shariah Compliant	Yes

## Key Shareholders

Khazanah National Bhd	41.1%
Mitsui & Co Ltd	18.0%
Employee Providend Fund	9.6%

Source: Affin Hwang, Bloomberg

Tan Jun Zhang  
(603) 2146 7487  
Junzhang.tan@affinhwang.com

**Segmental 2Q17 result commentary**

- i) **Singapore.** Revenue grew 10% yoy to RM958m, driven by 1.3% yoy growth in inpatient admissions and revenue intensity growth of 8.7% yoy. EBITDA margin improved by 2.1ppts to 26.9% due to the ramp up of Novena Hospital.
- ii) **Malaysia.** Revenue increased by 15% yoy to RM455m, on 4.8% yoy growth in inpatient admission and revenue intensity growth of 10.3% yoy driven by more complex cases and pricing adjustments.
- iii) **India and North Asia.** Revenue increased by 31% yoy and 29% yoy respectively. Gleneagles Hong Kong's RM68m start-up losses eroded Group's EBITDA.
- iv) **Acibadem.** Revenue grew by 10% yoy to RM954m. The consolidation of Bulgaria hospitals contributed to 40% yoy inpatient admissions growth and revenue intensity increased by 4% yoy. EBITDA declined by 9% due to Acibadem Altunizade, which opened in March 2017. Higher operating costs from medical inflation and depreciation of Lira against the US\$ were also the reasons of weaker EBITDA margin.

**Fig 1: Results Comparison**

FYE Dec (RMm)	2Q17	QoQ % chg	YoY % chg	1H17	YoY % chg	Comment
Revenue	2,771.8	3.2	12.1	5,456.7	10.3	10% yoy increase in revenue was attributed to organic growth of its existing operations and the continuous ramp up of new hospitals.
Op costs	(2,247.3)	(6.1)	18.1	(4,365.1)	15.7	
EBITDA	524.6	(7.5)	(8.1)	1,091.6	(7.1)	Pre-operating and start-up costs from GHK and Altunizade eroded the margin.
<i>EBITDA margin (%)</i>	<i>18.9</i>	<i>-2.2ppt</i>	<i>-4.1ppt</i>	<i>20.0</i>	<i>-3.7ppt</i>	
Depr and Amort	(250.8)	16.3	23.3	(466.4)	15.6	
EBIT	273.8	(22.1)	(25.5)	625.2	(18.9)	
<i>EBIT margin (%)</i>	<i>9.9</i>	<i>-3.2ppt</i>	<i>-5ppt</i>	<i>11.5</i>	<i>-4.1ppt</i>	
Int expense	(109.9)	22.0	59.8	(200.0)	50.3	Higher borrowing used for working capital, capex and potential acquisitions.
Int and other inc	24.3	(44.0)	8.3	67.6	68.0	
Associates	(0.1)	(106.5)	(102.8)	2.0	(76.4)	
Exceptional items	219.5	0.1	355.3	438.9	935.7	RM555m gain on disposal of interest in Apollo Hospital in March and May 2017.
<b>Pretax</b>	<b>407.5</b>	<b>(22.5)</b>	<b>9.0</b>	<b>933.6</b>	<b>28.0</b>	
<b>Core pretax</b>	<b>188.0</b>	<b>(38.7)</b>	<b>(42.3)</b>	<b>494.7</b>	<b>(28.0)</b>	
Tax	(102.1)	24.8	14.2	(183.9)	6.5	
<i>Tax rate (%)</i>	<i>25.1</i>	<i>9.5ppt</i>	<i>1.1ppt</i>	<i>19.7</i>	<i>-4ppt</i>	
MI	11.1	(56.7)	(129.1)	36.9	(149.3)	
<b>Net profit</b>	<b>316.5</b>	<b>(32.7)</b>	<b>28.6</b>	<b>786.6</b>	<b>63.3</b>	
EPS (sen)	3.8	(32.7)	28.4	9.6	63.3	
<b>Core net profit</b>	<b>86.2</b>	<b>(57.3)</b>	<b>(50.3)</b>	<b>288.0</b>	<b>(30.1)</b>	Below our expectations due to higher depreciation cost from 2 new hospitals and finance cost.

Source: Affin Hwang, Company data

**Equity Rating Structure and Definitions**


---

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

---

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest arising as a result of publication and distribution of investment research reports. Under no circumstances shall the Company, its associates and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Any opinions or estimates in this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors and/or employees may have an interest in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by:  
Affin Hwang Investment Bank Berhad (14389-U)  
A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
69, Jalan Raja Chulan,  
50200 Kuala Lumpur, Malaysia.

T : + 603 2146 3700  
F : + 603 2146 7630  
research@affinhwang.com

www.affinhwang.com